


**TOTAL SYNTHESIS OF (\pm)-AGELINE A,
A PHYSIOLOGICALLY ACTIVE CONSTITUENT OF AGELAS SPONGES**

Kazuhiko Asao, Hideo Iio, and Takashi Tokoroyama*


Faculty of Science, Osaka City University, Sumiyoshi-ku, Osaka 558, Japan

Summary: The monocyclic diterpene moiety of ageline A (1) was convergently constructed by the palladium-mediated coupling of C₉-terpene chain as vinyl bromide 10 and C₁₁-monocyclic segment as alkylzinc compound 16, which was obtained through a stereoselective cyclization and associated transformations. The appendage of 9-methyladenine ring to the diterpene unit led to the total synthesis of (+)-ageline A.


Recently a number of sesqui- and diterpenes with polar functionalities have been found as the metabolites of sea sponges of the genus *Agelas*¹ and they are featured by prominent bioactivity involving inhibitory effect on Na,K-ATPase.^{2,3} In continuation of the synthetic studies on these compounds,⁴ we concerned with the synthesis of ageline A⁵ (agelasine F^{1,3}), (1).



First our attention was focussed on the synthesis of the terpene unit⁶ and we envisaged the application of the folding strain control methodology⁷ for the stereoselective construction of the cyclohexane ring with *cis*-dimethyl groups, which was found to be feasible as reported in the preceding report.⁸ This synthetic plan necessitated the coupling of the terpene chains at unprecedented position⁹ (Scheme 1). We conceived to solve the problem by the metal-mediated coupling between the synthons 2 and 3, which would be the most convergent way. With this plan in mind the iodide 7 was derived from the epimeric mixture of the cyclohexanol 5 obtained by the cyclization of (2)-




Scheme 1



Scheme 2 Reagents: i, CrO_3 , $\text{H}_2\text{SO}_4/\text{Me}_2\text{CO}$; ii, $\text{HOCH}_2\text{CH}_2\text{OH}$, $\text{CSA}/\text{C}_6\text{H}_6$; iii, $\text{B}_2\text{H}_6/\text{THF}$, then H_2O_2 , NaOH ; iv, BnBr , NaH , $n\text{-Bu}_4\text{NI}/\text{THF}$; v, $1\text{M HCl}/\text{THF}$; vi, $\text{MeMgI}/\text{Et}_2\text{O}$; vii, SOCl_2 , $\text{C}_5\text{H}_5\text{N}/\text{CH}_2\text{Cl}_2$; viii, $\text{TsOH}/\text{diglyme}$; ix, Li/NH_3 ; x, MsCl , $\text{Et}_3\text{N}/\text{CH}_2\text{Cl}_2$; xi, $\text{NaI}/\text{Me}_2\text{CO}$; xii, PBr_3 , $\text{C}_5\text{H}_5\text{N}/\text{Et}_2\text{O}$; xiii, $\text{CH}_2\text{CO}^-\text{CHCO}_2\text{Me}/\text{THF}$; xiv, $(\text{EtO})_2\text{POCl}$; xv, DIBAL/THF


5,6-dimethyl-8-trimethylsilyloctanal⁸ and the vinyl bromide 10 was prepared from (*E*)-3-bromo-2-butanol (8)¹⁰ as shown in Scheme 2. The coupling of 2 and 3, which are optional in two modes of polarity combination, was first investigated between the iodide 7 and the cuprate derived from 10. Among the various modifications¹¹ of the cuprate used, only the mixed cuprate with 3-methoxy-3-methyl-1-butyne (THF , -20°C)¹² afforded the coupling product 4 *albeit* in low yield (6.7%). Obviously the cuprate linkage at a non-terminal vinylic position would pose steric drawback for the substitution.

To circumvent this difficulty we searched less convergent route to 4. The cyclic segment 7 was converted to vinyl iodide 12 by the substitution with lithium acetylide and subsequent zirconium-catalyzed carboalumination/iodination procedure.¹³ The palladium-catalyzed coupling^{14,15} of 12 with (*E*)-5-benzyloxy-3-methyl-3-pentenylzinc bromide (15), which was derivable from 3-butyne-1-ol as indicated in Scheme 3, afforded the diterpenoid compound 4 in 68% yield. Although the synthetic path thus developed was efficient enough for the preparation of 4 (50% overall yield from 7), we sought further to settle the problem of the terpenic chain linkage aimed at the outset, extending the Negishi's method to the reaction with non-terminal alkenyl



Scheme 3 Reagents: i, $\text{HC-CLi}/\text{DMSO}$; ii, Cp_2ZrCl_2 , $\text{Me}_3\text{Al}/\text{ClCH}_2\text{CH}_2\text{Cl}$; iii, I_2/THF ; iv, $t\text{-BuMe}_2\text{SiCl}$, Et_3N ; v, $t\text{-BuLi}/\text{Et}_2\text{O}$; vi, $\text{Me}_3\text{Al}/n\text{-C}_6\text{H}_{14}$; vii, $\text{BnOCH}_2\text{Cl}/\text{THF}$; viii, HF/MeCN ; ix, MsCl , $\text{C}_5\text{H}_5\text{N}$; x, $\text{NaI}/\text{Me}_2\text{CO}$; xi, ZnBr_2/THF ; xii, $\text{PdCl}_2\text{dppf}/\text{THF}$

halide. When the vinyl bromide **10** was treated with the zinc compound **16** derived from **7** in the presence of PdCl_2dppf , the coupling reaction did proceed smoothly to afford the product **4** in 66% yield. Thus the combination of a terpenic chain between C-3 and C-4 of the 3-methyl-2-butenyl unit now become feasible and this fact will enlarge the synthetic design of terpenic chains.



Scheme 4 Reagents: i, $t\text{-BuLi}/\text{Et}_2\text{O}$; ii, ZnBr_2/THF ; iii, **10**, PdCl_2dppf (3 mol%); iv, Li/NH_3 ; v, PBr_3 , $\text{C}_5\text{H}_5\text{N}/\text{Et}_2\text{O}$; vi, N^6 -methoxy-9-methyladenine/ MeCONMe_2 ; vii, Zn , $\text{H}_2\text{O}/\text{AcOH}$

To complete the synthesis of ageline A, **4** was transformed to the corresponding bromide **17**, with which the regioselective alkylation at the 7 position of 9-methyladenine ring was performed by the method previously established.⁴ The spectral data (UV, IR, ^1H and ^{13}C NMR) of the synthetic product were indistinguishable with those of authentic ageline A.² In the ^1H NMR spectrum¹⁶ we observed that the signals due to 2'-H and 8'-H, in addition to the resonance due to amino protons, showed concentration-dependent shifts: δ -values measured at the concentration of 80 mg, 4.8 mg, 2.4 mg, 1.2 mg/0.6 mL were 8.43, 8.48, 8.49, 8.50 (2'-H) and 10.40, 10.60, 10.69, 10.77 (8'-H) respectively.¹⁷ The reason may be ascribed to the propensity of the molecules to associate through the polar moiety.

In conclusion we have achieved the total synthesis of (\pm)-ageline A by a method involving the construction of the carbocyclic ring through a stereo-controlled cyclization reaction and the linking of the terpenic chains at unprecedented position.

Acknowledgements. We thank Dr. H. Nakamura, Mitsubishi-Kasei Institute of Life Science, for an authentic sample of ageline A. This work was partly supported by Grand-in-Aid from the Ministry of Education, Science and Culture, which is gratefully acknowledged.

References and notes

1. H. Nakamura, H. Wu, J. Kobayashi, M. Kobayashi, Y. Ohizumi, and Y. Hirata, *J. Org. Chem.*, **50**, 2494 (1985) and references cited therein. For further references see: H. Wu, H. Nakamura, J. Kobayashi, M. Kobayashi, Y. Ohizumi, and Y. Hirata, *Bull. Chem. Soc. Jpn*, **59**, 2495 (1986); R. Fathi-Afshar and T. M. Allen, *Can. J. Chem.*, **66**, 45 (1988).

2. H. Nakamura, H. Wu, Y. Ohizumi, and Y. Hirata, *Tetrahedron Lett.*, **25**, 2989 (1984).
3. H. Wu, H. Nakamura, J. Kobayashi, Y. Ohizumi, and Y. Hirata, *Tetrahedron Lett.*, **25**, 3719 (1984).
4. H. Iio, K. Asao, and T. Tokoroyama, *J. Chem. Soc., Chem. Commun.*, 774 (1985).
5. R. J. Capon and D. J. Faulkner, *J. Am. Chem. Soc.*, **106**, 1819 (1984).
6. The same terpenic unit, though enantiomeric, is contained in the structure of another *Agelas* constituent, agelasidine C. We have also achieved the synthesis of this compound utilizing the terpenic unit prepared in this report: K. Asao, H. Iio, and T. Tokoroyama, submitted for publication.
7. T. Tokoroyama, M. Tsukamoto, and H. Iio, *Tetrahedron Lett.*, **25**, 5067 (1984); T. Tokoroyama, K. Okada, and H. Iio, *J. Chem. Soc., Chem. Commun.*, submitted.
8. K. Asao, H. Iio, and T. Tokoroyama, preceding paper.
9. Recently a potential method was reported: N. Miyaura, T. Ishiyama, H. Sasaki, M. Ishikawa, M. Satoh, and A. Suzuki, *J. Am. Chem. Soc.*, **111**, 314 (1989).
10. M. Schlosser and E. Hammer, *Helv. Chim. Acta*, **57**, 2547 (1974).
11. B. H. Lipshutz, M. Koerner, and D. A. Parker, *Tetrahedron Lett.*, **28**, 945 (1987); B. H. Lipshutz, J. A. Kozlowski, D. A. Parker, S. L. Nguyen, and K. E. McCarthy, *J. Organometal. Chem.*, **285**, 437 (1985); B. H. Lipshutz, R. S. Wilhelm, and D. M. Floyd, *J. Am. Chem. Soc.*, **103**, 7672 (1981).
12. E. J. Corey, D. Floyd, and B. H. Lipshutz, *J. Org. Chem.*, **43**, 3418 (1978).
13. E. Negishi, D. E. Van Horn, A. O. King, and N. Okukado, *Synthesis*, 501 (1979).
14. E. Negishi, A. O. King, and N. Okukado, *J. Org. Chem.*, **42**, 1821 (1977).
15. T. Hayashi, M. Konishi, Y. Kobori, and M. Kumada, T. Higuchi, and K. Hirotsu, *J. Am. Chem. Soc.*, **106**, 158 (1984).
16. ¹H NMR(400 MHz, CDCl₃, 1.2 mg/mL): δ 0.84(3H, s), 0.85(3H, d, J = 7 Hz), 1.56(3H, s), 1.58(3H, s), 1.86 (3H, s), 4.10(3H, s), 5.02(1H, br s), 5.41 (1H, br s), 5.46(1H, br t, J = 7 Hz), 5.65(2H, br d, J = 7 Hz), 6.53(2H, br s), 8.50(1H, s), 10.77(1H, s).
17. At the extremely high concentration (80 mg/0.6 mL), the chemical shifts of even 14-H and 15-H showed some discrepancy from those measured in more dilute solution (14-H δ 5.50 vs. 5.46; 15-H δ 5.61 vs. 5.65). However we did not observed 'double' signals with respect to H-2' and H-8' resonances at any concentration as reported by Faulkner.⁵

(Received in Japan 24 July 1989)